Vanguard Capital Management
ABVC icon

Vanguard Capital Management’s ABVC BioPharma ABVC Stock Holding History

Vanguard Capital Management’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$603K Buy
569,150
+194,651
+52% +$216K ﹤0.01% 3656
2026
Q2 		$592K Buy
374,499
+183,925
+97% +$229K ﹤0.01% 3686
2026
Q1 		$185K Buy
+190,574
New +$315K ﹤0.01% 3810

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Vanguard Capital Management's ABVC Position: Q3 2026 in Review

Vanguard Capital Management increased its ABVC BioPharma (ABVC) stake by 52% in Q3 2026, buying an estimated $216K and bringing the position to 569,150 shares worth $603K. The position accounts for ﹤0.01% of the portfolio, ranked #3656.

Vanguard Capital Management first reported a position in ABVC in Q1 2026 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold ABVC as of Q3 2026.

  • Vanguard Capital Management held 569,150 shares of ABVC BioPharma worth $603K as of Q3 2026.
  • Vanguard Capital Management bought 194,651 ABVC BioPharma shares in Q3 2026, an estimated $216K.
  • ABVC BioPharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3656 holding.
  • Vanguard Capital Management first reported a position in ABVC BioPharma in Q1 2026 and has held it in 3 quarters since.
  • 11 funds tracked by Wall St. Rank held ABVC BioPharma as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.